Basit öğe kaydını göster

NSCLC molecular testing in Central and Eastern European countries

dc.contributor.authorOlszewski, Wlodzimierz
dc.contributor.authorRyska, Ales
dc.contributor.authorOz, Buge
dc.contributor.authorKovalszky, Ilona
dc.contributor.authorPlank, Lukas
dc.contributor.authorTimar, Jozsef
dc.contributor.authorBerzinec, Peter
dc.contributor.authorBrcic, Luka
dc.contributor.authorCufer, Tanja
dc.contributor.authorDziadziuszko, Rafal
dc.contributor.authorGottfried, Maya
dc.date.accessioned2021-03-05T14:16:16Z
dc.date.available2021-03-05T14:16:16Z
dc.identifier.citationRyska A., Berzinec P., Brcic L., Cufer T., Dziadziuszko R., Gottfried M., Kovalszky I., Olszewski W., Oz B., Plank L., et al., "NSCLC molecular testing in Central and Eastern European countries", BMC CANCER, cilt.18, 2018
dc.identifier.issn1471-2407
dc.identifier.othervv_1032021
dc.identifier.otherav_b65299ab-f1cb-43cb-8a3f-3f6ba8e0d624
dc.identifier.urihttp://hdl.handle.net/20.500.12627/121367
dc.identifier.urihttps://doi.org/10.1186/s12885-018-4023-4
dc.description.abstractBackground: The introduction of targeted treatments for subsets of non-small cell lung cancer (NSCLC) has highlighted the importance of accurate molecular diagnosis to determine if an actionable genetic alteration is present. Few data are available for Central and Eastern Europe (CEE) on mutation rates, testing rates, and compliance with testing guidelines.
dc.language.isoeng
dc.subjectOnkoloji
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectONKOLOJİ
dc.titleNSCLC molecular testing in Central and Eastern European countries
dc.typeMakale
dc.relation.journalBMC CANCER
dc.contributor.departmentCharles University Prague , ,
dc.identifier.volume18
dc.contributor.firstauthorID252165


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster